Hermann Am Mucke
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development. ...
Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight [0.03%]
用于治疗神经退行性疾病的硫丙酸衍生物：一项专利聚焦
Rami A Al-Horani
Rami A Al-Horani
The patent introduces a class of agents that target amyloid aggregation, and subsequently, reduce amyloid β-oligomer neurotoxicity. The class encompasses sulfopropanoic acid derivatives and is represented by tramiprosate and its prodrug AL...
Hermann A M Mucke
Hermann A M Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development. ...
Hermann A M Mucke
Hermann A M Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development. ...
Hermann Am Mucke
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development. ...
Trispecific anti-CLDN-18.2/CD3/CD28 antibodies for gastric cancer treatment [0.03%]
三特异性抗CLDN-18.2/CD3/CD28抗体治疗胃癌
Donaciano Flores-Robles,Antonio Celestino Montes,Jorge Antonio Perez Saldaña et al.
Donaciano Flores-Robles et al.
Claudin-18.2 is an overexpressed molecule in gastric cancer, which is why it is considered a potential therapeutic target. WO2024082060 describes trispecific antibodies directed against CDLN-18.2/CD3/CD28, and gastric cancer treatment metho...
Jorge Antonio Perez Saldaña,Donaciano Flores-Robles,Antonio Celestino Montes et al.
Jorge Antonio Perez Saldaña et al.
Introduction: Mesothelin protein is an overexpressed molecule in epithelioid mesothelioma, epithelial ovarian cancer, and pancreatic adenocarcinoma, which is why it is considered a potential therapeutic target. ...
Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma [0.03%]
双特异性的抗CD38/CD28抗体在治疗多发性骨髓瘤中的应用
Martin Perez-Santos,Maricruz Anaya-Ruiz,Donaciano Flores-Robles et al.
Martin Perez-Santos et al.
Introduction: Since CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment. Areas c...
Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations [0.03%]
蛋白酶靶向嵌合体（PROTAC）在肿瘤学中的应用：专利和监管考量综述
Sowndharya M,Ramesh Joga,Kajal Gandhi et al.
Sowndharya M et al.
Introduction: Proteolysis Targeting Chimeras (PROTACs) represents a groundbreaking advancement in drug discovery and targeted protein degradation. Unlike traditional small-molecule inhibitors, PROTACs leverage the cell's ...
Hermann A M Mucke
Hermann A M Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development. ...